In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death
- PMID: 35667068
- DOI: 10.7326/J22-0038
In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death
Abstract
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386:1397-408. 35172054.
Comment on
-
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources